### About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

### Details of Drug Reviewed

<table>
<thead>
<tr>
<th>Drug</th>
<th>Umeclidinium-vilanterol</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brand Name</strong></td>
<td>Anoro™ Ellipta™</td>
</tr>
<tr>
<td><strong>Dosage Form(s)</strong></td>
<td>62.5 mcg/25 mcg dry powder for oral inhalation</td>
</tr>
<tr>
<td><strong>Manufacturer</strong></td>
<td>GlaxoSmithKline Inc.</td>
</tr>
</tbody>
</table>

#### Submission Review

- **Use Reviewed**: Chronic obstructive pulmonary disease (COPD)
- **Common Drug Review (CDR)**: Yes. CDR recommended: [List with criteria](https://www.cadth.ca/node/88649). Visit the CDR website for more details:
-**Drug Benefit Council (DBC)**: DBC met on February 2, 2015. DBC considered various inputs including: final review completed by the Common Drug Review (CDR) on January 15, 2015, which included clinical and pharmacoeconomic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC). The DBC also considered Clinical Practice Reviews from one specialist and one general physician, as well as a Budget Impact Assessment. The DBC did not receive any Patient Input Questionnaire responses from patients, caregivers, or Patient Groups.

#### Drug Coverage Decision

- **Limited Coverage Benefit.** Access the [umeclidinium-vilanterol criteria](https://www.gov.bc.ca/pharmacarespecialauthority).
- **Date**: August 11, 2015
- **Reason(s)**: Drug coverage decision is consistent with the DBC recommendation.
  - The drug demonstrated some efficacy advantage compared to tiotropium.
  - Based on economic considerations, the drug is cost effective and offers value for money.
- **Other Information**: None
The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the Drug Benefit Council (DBC) gives advice to the Ministry. The DBC looks at:
- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:
- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. Drug Review Process and PharmaCare program for more information.

This document is intended for information only.
It does not take the place of advice from a physician or other qualified health care provider.